Biclonal and hypodiploid multiple myeloma.
Plasma cell DNA and RNA content was measured by flow cytometry of acridine orange-stained bone marrow cells from 72 untreated patients with multiple myeloma. Biclonal or hypodiploid DNA stemlines were identified in 10 patients, nine of whom had a low RNA content and did not have response to chemotherapy. Biclonal tumors often showed atypical myeloma protein changes with chemotherapy, suggesting that one clone was reduced whereas the other remained unchanged. These findings suggest a genetic basis for the resistance of low RNA tumors to chemotherapy.
L
L
Smith
B
B
Barlogie
R
R
Alexanian
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001536:Bence Jones Protein / Q000032:analysis; D001853:Bone Marrow / Q000032:analysis; D004273:DNA, Neoplasm / Q000032:analysis; D004171:Diploidy; D004351:Drug Resistance; D005434:Flow Cytometry; D006801:Humans; D009101:Multiple Myeloma / Q000032:analysis* / Q000188:drug therapy / Q000401:mortality; D010950:Plasma Cells / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis
D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D001536:Bence Jones Protein